
CLAIMS

1. Use of an antisense oligomer conjugate of Formula (IV):



(IV),

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating Duchenne muscular dystrophy (DMD) in a primate subject in need thereof, wherein the primate subject has a mutation of the dystrophin gene that is amenable to exon 45 skipping.

2. Use of an antisense oligomer conjugate of Formula (IV), as defined in claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for restoring an mRNA reading frame to induce dystrophin production in a primate subject having a mutation of the dystrophin gene that is amenable to exon 45 skipping.

3. The use of claim 1 or 2, wherein the use comprises administering to the primate subject a pharmaceutical composition comprising the antisense oligomer conjugate of Formula (IV) or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

4. Use of a pharmaceutical composition comprising an antisense oligomer conjugate of Formula (IV), as defined in claim 1, or a pharmaceutically acceptable salt thereof, and a


pharmaceutically acceptable carrier, in the manufacture of a medicament for excluding exon 45 from dystrophin pre-mRNA during mRNA processing in a primate subject having a mutation of the dystrophin gene that is amenable to exon 45 skipping.

5. Use of a pharmaceutical composition comprising an antisense oligomer conjugate of Formula (IV), as defined in claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, in the manufacture of a medicament for binding exon 45 of dystrophin pre-mRNA in a primate subject having a mutation of the dystrophin gene that is amenable to exon 45 skipping.

6. The use of any one of claims 1 to 5, wherein the subject is human.

7. The use of any one of claims 1 to 6, wherein the antisense oligomer conjugate is in the form of a pharmaceutically acceptable salt.

8. The use of claim 7, wherein the antisense oligomer conjugate is in the form of a pharmaceutically acceptable salt of Formula (IVA):



(IVA).